- AU$92.05bn
- AU$107.79bn
- $15.80bn
Brief: CSL Limited Appoints Deborah Waterhouse As CEO And Managing Director
Australia's CSL appoints Deborah Waterhouse as CEO
Early US flu season, current strain may signal risk for younger people; doctors urge shots
Sanofi avoids fine as EU accepts offer to stop disparaging rival vaccine (updated)
Sanofi avoids fine as EU accepts offer to stop disparaging rival vaccine
Australia's CSL rises after Jefferies sees plasma yield upside
Australia's CSL set for weekly gain on rare diseases drug deal
Haemonetics surges as CSL plans to move all US plasma centers to its devices
Brief: CSL Expands Relationship With Haemonetics Corporation
Citi raises CSL's PT after $1.6 billion Alentis deal
Brief: CSL Limited Prices Us$1.5 Billion In Corporate Bonds
Factbox: Global healthcare companies invest billions to boost US presence
Australia's CSL gains as Jefferies hikes price target after Alentis licensing deal
Jefferies raise price target on Australia's CSL after Alentis licensing deal
Brief: CSL Limited Enters Exclusive Agreement With Alentis Therapeutics
CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis (updated)
Australia's CSL strikes kidney, liver disease drug deal worth up to $1.6 billion
US FDA advisers recommend flu vaccine strains for 2027 Southern Hemisphere season (updated)
US FDA advisers recommend flu vaccine strains for 2027 Southern Hemisphere season